Skip to main content

Table 3 Aggregate health-related quality of life (HRQoL) scores in some individual studies

From: Reliability of generic quality-of-life instruments in assessing health-related quality of life among children and adolescents with idiopathic nephrotic syndrome: a systematic review

Study authors Study design HRQoL score (median or mean/SD score) HRQoL score (median or mean/SD score)
Selewski et al. [22] Longitudinal cohort study 68.6 ± 16.0* 73.7 ± 17.8**
Agrawal et al. [17] Cross-sectional case–control study 65, interquartile range = 59–68.75 62.2††, interquartile range = 58.05–65.78
Khanjari et al. [23] Prospective case–control study 65.5 ± 12.6 64.6 ± 8.5‡‡
78.1 ± 8.5 65.1 ± 7.7‡‡
Roussel et al. [16] Cross-sectional observational study 76.2 72.6 ¶¶
71.4 ± 16 § 61.6 ± 19.5 §§
  1. *Mean score for children with prevalent nephrotic syndrome (disease duration at baseline ≥ 30 days) **Mean score for children with incident nephrotic syndrome (disease duration at baseline < 30 days) Median score for children with nephrotic syndrome ††Mean score for children with other chronic diseases Mean scores for children with nephrotic syndrome before and after blended training ‡‡Mean scores of children with nephrotic syndrome before and after routine interventions Mean global score for nephrotic patients on oral immunosuppressive drug ¶¶Mean global score for nephrotic patients on intravenous rituximab §Mean score on ‘school functioning domain’ for nephrotic patients on oral immunosuppressive drug §§Mean score on ‘school functioning domain’ for nephrotic patients on intravenous rituximab, SD, standard deviation